Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Illumina, Inc. - Common Stock (NQ: ILMN )

136.67 -0.70 (-0.51%)
Streaming Delayed Price Updated: 4:00 PM EST, Jan 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Illumina, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Illumina Unusual Options Activity For May 07
Via Benzinga
Beyond The Numbers: 6 Analysts Discuss Illumina Stock
Via Benzinga
Wall Street Looks To Feed Off Apple's Post-Earnings Power But Key Jobs Data May Upset The Cart: Analyst Says 'A Lot Of These Clouds Will Lift' If This Happens
Stocks look set to carry forward the upward momentum on Friday amid some earnings cheer, although a tinge of nervousness is evident ahead of the all-important non-farm payrolls report. 
Via Benzinga
ILMN Stock Earnings: Illumina Beats EPS, Beats Revenue for Q1 2024
ILMN stock results show that Illumina beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages. 
Via Benzinga
Topics Stocks
Exposures US Equities
Looking Into Illumina's Recent Short Interest
Via Benzinga
Critical Insights From Illumina Analyst Ratings: What You Need To Know
Via Benzinga
Nasdaq, S&P 500 Futures Rise Ahead Of Apple Earnings: Why This Analyst Thinks 'No Cut' Scenario May Not Be Negative For Market
U.S. stocks look to push ahead on a positive path, now that the Federal Reserve’s rate decision is in the rearview mirror. Major index futures point to a positive open on Thursday. 
Via Benzinga
Topics Stocks
Exposures US Equities
3 Gene Editing Stocks with the Potential to Make You an Overnight Millionaire
Pay close attention to gene editing stocks. By 2028, according to MarketsandMarkets, the market could be worth about $10.6 billion. 
Via InvestorPlace
Jim Cramer Rejects Illumina As 'It's Not Well-Run,' Recommends Buying This Tech Stock 'Right Here, Right Now'
Jim Cramer doesn't recommend buying Dynatrace stock due to its high price. Canopy Growth is the best pot stock. BrightSpring, Illumina, and Bank of America also mentioned. Cramer recommends buying Palo... 
Via Benzinga
Topics Cannabis
Exposures Cannabis
The Cathie Wood Stock Shuffle: 4 Names She’s Loving, 3 She’s Leaving
Investing with the Ark Invest guru is a roller coaster ride, but she always keeps her big ideas for the future in front of her. 
Via InvestorPlace
Jim Cramer Isn't Going With This Tech Company: 'It's Complicated. I'm A Nvidia Guy'
On CNBC’s "Mad Money Lightning Round," Jim Cramer recommended buying Uber Technologies, Inc. (NYSE: UBER). 
Via Benzinga
Nasdaq’s Nosebleed Section: 3 Expensive Stocks to Sell Before It’s Too Late
Investors might want to be wary and dump these expensive Nasdaq stocks to sell before their impending and potentially violent corrections. 
Via InvestorPlace
Large-Cap Stocks In Trouble: Here Are The 10 Worst Performers Over The Past 12 Months
Over the past 12 months, 10 Large-Cap stocks have underperformed all others. 
Via Talk Markets
Why Illumina Stock Zoomed Higher on Thursday
The company's chances for winning an important legal battle have improved dramatically. 
Via The Motley Fool
EU Antitrust Regulators Overstepped in Illumina-Grail Deal, Says Court Adviser
EU antitrust advisor criticizes decision blocking Illumina's $7.1 billion bid for Grail, citing overreach. Impact on Qualcomm deal scrutinized. Commission's jurisdiction challenged amid legal battles.... 
Via Benzinga
Icahn’s All-In: 3 Stocks Billionaire Carl Icahn Is Betting Big On
Carl Icahn, the corporate raider turned activist investor, has put most of his master limited partnership' portfolio into just three stocks. 
Via InvestorPlace
Gene Sequencing Firm Illumina Escapes Carl Icahn's Second Proxy Battle Amid Grail Divestment Efforts
Carl Icahn halts new challenge to Illumina's board, sparing the gene sequencing giant a second proxy battle. Focus shifts to legal action over Grail acquisition. 
Via Benzinga
Earnings Crushers: Unveiling Q4’s 3 Top Stock Superstars
Although there were many earnings winners in the fourth quarter, these three picks have more promise than their counterparts. 
Via InvestorPlace
3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise
Discover the pivotal roles of cancer-fighting biotech stocks that are advancing cancer research and subsequently, their financial growth. 
Via InvestorPlace
7 No-Frills Dividend Stocks for Your Must-Own List
Income investors don't need to invest in risky businesses when no-frills dividend stocks get the job done just fine. 
Via InvestorPlace
Over $1M Bet On This Industrial Stock? Check Out These 4 Stocks Insiders Are Buying
Although U.S. stocks closed lower on Monday, there were a few notable insider trades. 
Via Benzinga
Why Illumina Stock Mashed the Market on Monday
Investors usually get more bullish when a top manager buys more heavily into their company. 
Via The Motley Fool
Activist Investor Alert: The Top 3 Stocks Carl Icahn Is Targeting in 2024
For those who want to invest alongside the legendary financier and activist investor, these are the top Carl Icahn stocks right now. 
Via InvestorPlace
3 Gene Editing Stocks With Unprecedented Surge Potential
While CRISPR will certainly be exciting to watch, here are some other gene-editing stocks with unprecedented surge potential. 
Via InvestorPlace
Why Take-Two Interactive Software Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Take-Two Interactive Software, Inc. (NASDAQ: TTWO) fell sharply during Friday’s session following third-quarter results. 
Via Benzinga
DNA Sequencing Kit Provider Illumina's Q4 Earnings Edge Above Street Estimates, Works To Resolve GRAIL Quickly
Illumina exceeds Q4 2023 expectations with $1.12 billion sales, up 4% YoY. CEO Jacob Thaysen anticipates growth and outlines strategic priorities for 2024. 
Via Benzinga
US Stocks Set To Open Higher, Finish Week Stronger Amid Mixed Earnings: Analyst Sees Another Leg-Up Ahead Of Historically Weak March
The upward momentum that has been in play in recent sessions could cushion the market, especially as most major indices are in uncharted territory. 
Via Benzinga
Expedia Reports Q4 Results, Joins Pinterest, Affirm Holdings And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures trading lower by around 15 points on Friday. 
Via Benzinga
Topics Stocks
Exposures US Equities
S&P 500 Tests Resistance At 5,000, ARM Rockets, Oil Rebounds: What's Driving Markets Thursday?
Major U.S. stock averages traded on a mixed note at midday in New York, with the S&P 500 grappling with the psychological resistance level of 5,000, while the tech-heavy Nasdaq 100 managed to reach... 
Via Benzinga
Topics Stocks
Exposures US Equities
< Previous 1 2 3 4 5 6 7 8 9
...
19 20 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.